CN104168956A - 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 - Google Patents

臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 Download PDF

Info

Publication number
CN104168956A
CN104168956A CN201280059376.9A CN201280059376A CN104168956A CN 104168956 A CN104168956 A CN 104168956A CN 201280059376 A CN201280059376 A CN 201280059376A CN 104168956 A CN104168956 A CN 104168956A
Authority
CN
China
Prior art keywords
sema4d
antibody
binding molecule
bbb
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280059376.9A
Other languages
English (en)
Chinese (zh)
Inventor
E·S·史密斯
M·佐德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaccinex Inc
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Priority to CN201910351743.6A priority Critical patent/CN110105452A/zh
Publication of CN104168956A publication Critical patent/CN104168956A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280059376.9A 2011-10-11 2012-10-11 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 Pending CN104168956A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910351743.6A CN110105452A (zh) 2011-10-11 2012-10-11 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161545809P 2011-10-11 2011-10-11
US61/545,809 2011-10-11
US201161555726P 2011-11-04 2011-11-04
US61/555,726 2011-11-04
US201261593641P 2012-02-01 2012-02-01
US61/593,641 2012-02-01
PCT/US2012/059757 WO2013055922A1 (en) 2011-10-11 2012-10-11 Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910351743.6A Division CN110105452A (zh) 2011-10-11 2012-10-11 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途

Publications (1)

Publication Number Publication Date
CN104168956A true CN104168956A (zh) 2014-11-26

Family

ID=48082436

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280059376.9A Pending CN104168956A (zh) 2011-10-11 2012-10-11 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途
CN201910351743.6A Pending CN110105452A (zh) 2011-10-11 2012-10-11 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910351743.6A Pending CN110105452A (zh) 2011-10-11 2012-10-11 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途

Country Status (16)

Country Link
US (2) US20130095118A1 (https=)
EP (1) EP2766093B1 (https=)
JP (2) JP6395606B2 (https=)
KR (1) KR101999872B1 (https=)
CN (2) CN104168956A (https=)
AU (1) AU2012322721B2 (https=)
BR (1) BR112014008885B1 (https=)
CA (1) CA2851805C (https=)
DK (1) DK2766093T3 (https=)
EA (1) EA029023B1 (https=)
ES (1) ES2669209T3 (https=)
IL (1) IL232072B (https=)
MX (1) MX353550B (https=)
PT (1) PT2766093T (https=)
SG (1) SG11201401458UA (https=)
WO (1) WO2013055922A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325213A (zh) * 2017-02-22 2019-10-11 瓦西尼斯公司 神经退行性或神经炎性疾病中胶质细胞活化的早期检测
CN113456813A (zh) * 2021-07-26 2021-10-01 苏州大学 Semaphorin7A单克隆抗体在制备用于治疗血栓及脑血管疾病药物方面的应用
CN113614222A (zh) * 2019-01-22 2021-11-05 麻省理工学院 体外人血脑屏障
CN113660951A (zh) * 2019-03-29 2021-11-16 中外制药株式会社 含有抗il-6受体抗体的抑制bbb功能低下的抑制剂

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2647823T3 (es) 2009-05-08 2017-12-26 Vaccinex, Inc. Anticuerpos anti-CD100 y métodos de uso de los mismos
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
MX377858B (es) 2013-06-25 2025-03-11 Vaccinex Inc Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos.
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
US10973930B2 (en) 2016-02-18 2021-04-13 The Penn State Research Foundation Generating GABAergic neurons in brains
IL262232B2 (en) 2016-04-22 2024-06-01 Vaccinex Inc Integral membrane protein display on poxvirus extracellular enveloped virions
KR102449406B1 (ko) 2016-08-02 2022-09-29 백시넥스 인코포레이티드 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법
EP3512937B1 (en) * 2016-09-13 2024-10-09 Angiocrine Bioscience, Inc. Blood-brain barrier comprising engineered endothelial cells
WO2018204895A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
CA3076099A1 (en) * 2017-09-22 2019-03-28 Kite Pharma, Inc. Linkers for chimeric antigen receptors
EP3746109A4 (en) * 2018-02-02 2021-11-03 The Penn State Research Foundation METHODS AND MATERIALS FOR TREATING BRAIN INJURY
US11597765B2 (en) 2020-06-25 2023-03-07 Vaccinex, Inc. Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
EP3973979A1 (en) * 2020-09-25 2022-03-30 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth A tight junction (zonulae occludentes) protein for use in treating or preventing epilepsy
WO2023012314A1 (en) * 2021-08-05 2023-02-09 Lifearc Anti-plexin-b1 antibodies
US20230101618A1 (en) * 2021-09-27 2023-03-30 Vaccinex, Inc. Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
CN114539204B (zh) * 2022-03-23 2023-08-22 福建金兰厚普生物科技有限公司 己糖激酶抑制剂及其合成方法和应用
AU2024247601A1 (en) * 2023-03-28 2025-10-23 Nb Health Laboratory Co., Ltd. Antibody, nucleic acid, cell and drug

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037851A1 (en) * 1997-07-09 2002-03-28 Bernhard Fleckenstein Human semaphorin L (H-SemaL) and corresponding semaphorins in other species
US20100285036A1 (en) * 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-CD100 Neutralizing Antibodies and Methods of Using the Same

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
WO1998046769A1 (en) 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
AU776865B2 (en) 1998-11-10 2004-09-23 University Of Rochester T cells specific for target antigens and methods and vaccines based thereon
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
CN1329060A (zh) 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人semaphorin蛋白9和编码这种多肽的多核苷酸
AU2002329540A1 (en) 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20080219974A1 (en) 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
DE60334453D1 (de) 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
CA2548180C (en) 2003-12-04 2014-02-04 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
EP1773885B1 (en) 2004-08-05 2010-04-21 Genentech, Inc. Humanized anti-cmet antagonists
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
AU2006235271B2 (en) 2005-04-07 2011-05-19 Novartis Vaccines And Diagnostics Inc. SEMA4D in cancer diagnosis, detection and treatment
CA2627966A1 (en) 2005-11-16 2007-05-24 Novartis Ag Biomarkers for anti-nogo-a antibody treatment in spinal cord injury
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
US8257706B2 (en) 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
KR20120017469A (ko) * 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
JP5357782B2 (ja) 2007-02-21 2013-12-04 バクシネックス インコーポレーティッド 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
US20090181035A1 (en) 2008-01-10 2009-07-16 Genentech, Inc. Plexind1 agonists and their use
MX2011012147A (es) 2009-05-15 2012-06-19 Irx Therapeutics Inc Inmunoterapia de vacuna.
JP5500944B2 (ja) 2009-10-29 2014-05-21 三菱電機株式会社 加熱調理器
NZ604464A (en) 2010-06-14 2014-03-28 Vaccinex Inc Anti-vegf antibodies and uses thereof
AU2011295902B2 (en) 2010-09-02 2014-12-04 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
KR102003571B1 (ko) 2011-05-13 2019-07-24 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 골형성 촉진제
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
NZ629828A (en) 2012-03-02 2017-05-26 Vaccinex Inc Methods for the treatment of b cell-mediated inflammatory diseases
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
EP2951204B1 (en) 2013-01-31 2019-05-22 Vaccinex, Inc. Methods for increasing immunoglobulin a levels
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
MX377858B (es) 2013-06-25 2025-03-11 Vaccinex Inc Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos.
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
IL262232B2 (en) 2016-04-22 2024-06-01 Vaccinex Inc Integral membrane protein display on poxvirus extracellular enveloped virions
KR102449406B1 (ko) 2016-08-02 2022-09-29 백시넥스 인코포레이티드 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법
CN110325213A (zh) 2017-02-22 2019-10-11 瓦西尼斯公司 神经退行性或神经炎性疾病中胶质细胞活化的早期检测

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037851A1 (en) * 1997-07-09 2002-03-28 Bernhard Fleckenstein Human semaphorin L (H-SemaL) and corresponding semaphorins in other species
US20100285036A1 (en) * 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-CD100 Neutralizing Antibodies and Methods of Using the Same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TATSUSADA OKUNO ET AL.: "Roles of Sema4D-Plexin-B1 Interactions in the Central Nervous System for Pathogenesis of Experimental Autoimmune Encephalomyelitis", 《THE JOURNAL OF IMMUNOLOGY》, vol. 184, 28 December 2009 (2009-12-28), pages 1499 - 1506, XP055149724, DOI: doi:10.4049/jimmunol.0903302 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325213A (zh) * 2017-02-22 2019-10-11 瓦西尼斯公司 神经退行性或神经炎性疾病中胶质细胞活化的早期检测
CN113614222A (zh) * 2019-01-22 2021-11-05 麻省理工学院 体外人血脑屏障
CN113660951A (zh) * 2019-03-29 2021-11-16 中外制药株式会社 含有抗il-6受体抗体的抑制bbb功能低下的抑制剂
CN113456813A (zh) * 2021-07-26 2021-10-01 苏州大学 Semaphorin7A单克隆抗体在制备用于治疗血栓及脑血管疾病药物方面的应用

Also Published As

Publication number Publication date
EP2766093A4 (en) 2015-03-25
NZ623856A (en) 2016-04-29
CA2851805A1 (en) 2013-04-18
AU2012322721A1 (en) 2013-05-16
EP2766093B1 (en) 2018-02-21
EP2766093A1 (en) 2014-08-20
US20130095118A1 (en) 2013-04-18
CA2851805C (en) 2021-12-28
MX2014004457A (es) 2014-06-05
KR101999872B1 (ko) 2019-07-12
BR112014008885B1 (pt) 2021-02-17
IL232072A0 (en) 2014-05-28
WO2013055922A1 (en) 2013-04-18
JP6395606B2 (ja) 2018-09-26
BR112014008885A2 (pt) 2017-04-18
SG11201401458UA (en) 2014-07-30
MX353550B (es) 2018-01-18
CN110105452A (zh) 2019-08-09
EA201490768A1 (ru) 2014-09-30
US20190358321A1 (en) 2019-11-28
ES2669209T3 (es) 2018-05-24
IL232072B (en) 2021-01-31
EA029023B1 (ru) 2018-01-31
JP2017193569A (ja) 2017-10-26
AU2012322721B2 (en) 2016-05-05
DK2766093T3 (en) 2018-06-06
JP2014530239A (ja) 2014-11-17
US11534488B2 (en) 2022-12-27
KR20140076616A (ko) 2014-06-20
PT2766093T (pt) 2018-05-18

Similar Documents

Publication Publication Date Title
US11534488B2 (en) Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
AU2021202095B2 (en) Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
US9512224B2 (en) Use of semaphorin-4D binding molecules for treatment of atherosclerosis
CN104619341A (zh) 脑信号蛋白-4d结合分子在促进中风后的神经发生中的用途
NZ623856B2 (en) Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20141126

RJ01 Rejection of invention patent application after publication